CITATION REPORT List of articles citing

Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak "stable" patients on anti-HBV therapy

DOI: 10.1038/s41598-018-21179-2 Scientific Reports, 2018, 8, 2989.

Source: https://exaly.com/paper-pdf/68978286/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
22	Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries. <i>Disease Markers</i> , 2019 , 2019, 3862024	3.2	7
21	SHG/TPEF-based image technology improves liver fibrosis assessment of minimally sized needle biopsies. <i>Hepatology International</i> , 2019 , 13, 501-509	8.8	3
20	On-treatment changes of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon add-on therapy. <i>Journal of Medical Virology</i> , 2019 , 91, 1499-1509	19.7	2
19	Medical liver biopsy: background, indications, procedure and histopathology. <i>Frontline Gastroenterology</i> , 2020 , 11, 40-47	2.6	24
18	Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1170-1178.e6	6.9	39
17	Regression of liver fibrosis: evidence and challenges. <i>Chinese Medical Journal</i> , 2020 , 133, 1696-1702	2.9	8
16	An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials. <i>Diagnostics</i> , 2020 , 10,	3.8	5
15	Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2582-2591.e6	6.9	22
14	Safety and therapeutic effects of anti-fibrotic Traditional Chinese Medicine Fuzheng Huayu on persistent advanced stage fibrosis following 2 years entecavir treatment: Study protocol for a single arm clinical objective performance criteria trial. <i>Contemporary Clinical Trials Communications</i> ,	1.8	1
13	Second-harmonic generation (SHG) microscopy and hepatic venous pressure gradient-based validation of a novel histological staging system for alcoholic hepatitis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 479, 493-506	5.1	
12	Evaluation of HCV-related liver fibrosis post-successful DAA therapy. <i>Egyptian Liver Journal</i> , 2021 , 11,	1.6	O
11	Semiautomated quantification of the fibrous tissue response to complex three-dimensional filamentous scaffolds using digital image analysis. <i>Journal of Biomedical Materials Research - Part A</i> , 2021 ,	5.4	1
10	Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients. <i>PLoS ONE</i> , 2020 , 15, e0239624	3.7	2
9	Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis. <i>Journal of Clinical and Translational Hepatology</i> , 2020 , 8, 277-284	ļ ^{5.2}	2
8	Quantification of Liver Fibrosis A Comparative Study. Applied Sciences (Switzerland), 2020, 10, 447	2.6	10
7	Predict Early Recurrence of Resectable Hepatocellular Carcinoma Using Multi-Dimensional Artificial Intelligence Analysis of Liver Fibrosis. <i>Cancers</i> , 2021 , 13,	6.6	O
6	Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH. <i>Journal of Hepatology</i> , 2022 ,	13.4	2

CITATION REPORT

Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial. **2022**, 298, 115599

4	Non-alcoholic fatty liver disease: the pathologist⊠ perspective.	O
3	Hepatic venous pressure gradient evaluates the Scheuer stage of liver fibrosis by transjugular liver biopsy: a multicenter study. 2023 ,	0
2	Cellular and Molecular Techniques. 2024 , 96-121	O
1	Hepatitis Due to Hepatotropic Viruses. 2024 , 402-447	О